Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

JAMA

Volumn 295, Issue 3, 2006, Pages 299-305

  Barton Grossman, H ^a   Soloway, Mark ^b   Messing, Edward ^c   Katz, Giora ^d,e   Stein, Barry ^f   Kassabian, Vahan ^g   Shen, Yu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Lakeshore Urology   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g Georgia Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

ADULT; AGED; ANAMNESIS; ARTICLE; BIOASSAY; BLADDER BIOPSY; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POINT OF CARE PROTEOMIC ASSAY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RECURRENT CANCER; URINALYSIS;

EID: 30944466321     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.3.299     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Surveillance, Epidemiology, and End Results Program. Available at: http://www.seer.cancer.gov/csr /1975_2002. Accessed December 23, 2005.
3. National Comprehensive Cancer Network. Available at: http://www.nccn.org/ professionals /physician_gls/PDF/bladder.pdf. Accessed December 23, 2005.
4. Frimberger D, Zaak D, Hofstetter A. Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of the bladder. Semin Urol Oncol. 2000;18:264-272.
5. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol. 1995;153:564-572.
6. Farrow GM. Urine cytology in the detection of bladder cancer: a critical approach. J Occup Med. 1990;32:817-821.
7. Brown FM. Urine cytology: is it still the gold standard for screening? Urol Clin North Am. 2000;27:25-37.
8. Badalament RA, Hermansen DK, Kimmel M, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer. 1987;60:1423-1427.
9. Matzkin H, Moinuddin SM, Soloway MS. Value of urine cytology versus bladder washing in bladder cancer. Urology. 1992;39:201-203.
10. de Kok JB, van Balken MR, Roelofs RW, van Aarssen YA, Swinkels DW, Klein Gunnewiek JM. Quantification of hTERT mRNA and telomerase activity in bladder washings of patients with recurrent urothelial cell carcinomas. Clin Chem. 2000;46:2003-2007.
11. Murphy WM, Crabtree WN, Jukkola AF, Soloway MS. The diagnostic value of urine versus bladder washing in patients with bladder cancer. J Urol. 1981;126:320-323.
12. Berezney R, Coffey DS. Identification of a nuclear matrix protein. Biochem Biophys Res Commun. 1974;60:1410-1417.
13. Fey EG, Krochmalnic G, Penman S. The nonchromatin substructures of the nucleus: the ribonucleoprotein (RNP)-containing and RNP-depleted matrices analyzed by sequential fractionation and resinless section electron microscopy. J Cell Biol. 1986;102:1654-1665.
14. Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eukaryotic cells. Cell. 1980;19:527-536.
15. Zeitlin S, Parent A, Silverstein S, Efstratiadis A. Pre-mRNA splicing and the nuclear matrix. Mol Cell Biol. 1987;7:111-120.
16. Nakayasu H, Berezney R. Mapping replicational sites in the eukaryotic nucleus. J Cell Biol. 1989;108:1-11.
17. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point of care proteomic assay: a multicenter study. JAMA. 2005;293:810-816.
18. US Food and Drug Administration Premarket Approval (PMA) Database: PMA 940035. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs /cfPMA/PMA.cfm?ID=7411. Accessed February 10, 2005.
19. Cancer Staging Manual. 5th ed. Philadelphia, Pa: American Joint Committee on Cancer; 1997.
20. Durkalski VL, Palesch Y, Lipsitz S, Rust P. The analysis of clustered matched-pair data. Stat Med. 2003;22:2417-2428.
21. Holmang S, Hedelin H, Anderstron C, Johansson SL. The relationship among multiple recurrences, progression, and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995;153:1823-1826.
22. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-1086.
23. Zaak D, Stepp H, Kriegmair M, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid-results of 1012 fluorescence endoscopies. Urology. 2001;57:690-694.
24. Schneeweiss S, Kriegmair M, Stepp H. Is everything all right if nothing seems wrong? a simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol. 1999;161:1116-1119.
25. Kriegmair M, Baumgartner R, Knuechel R, Stepp H, Hofstadter R, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105-110.
26. Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol Clin North Am. 1979;6:599-612.
27. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174:862-866.
28. Sachs MD, Daniltchenko DI, Riedl CR, et al. Fluorescence detection with 5-aminolevulinic acid (ALA) reduces risk of tumor recurrence and progression in patients with superficial bladder cancer: 5 year results of a prospective randomized trial. J Urol. 2005;173:247.
29. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003;169:110-115.
30. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003;170(4 pt 1):1085-1087.
31. May M, Nitzke T, Helke C, Vogler H, Hoschke B. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol. 2004;38:231-235.
32. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharmacoeconomics. 2003;21:1315-1330.
33. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Harihan A, Moriera A. The significance of adult hematuria: 1,000 hematuria evaluations including a riskbenefit and cost-effectiveness analysis. J Urol. 1989;141:350-355.
34. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. ImmunoCyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999;161:1486-1489.
35. Pfister C, Chautard D, Devonec M, et al. ImmunoCyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol. 2003;169:921-924.
36. Mian C, Lodde M, Comploj E, et al. Liquid-based cytology as a tool for the performance of uCyt+ and UroVysion multicolour-FISH in the detection of urothelial carcinoma. Cytopathology. 2003;14:338-342.
37. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950-1954.
38. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
39. Halling KC, King W, Sokolova IA, et al. A comparison of BTA Stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001-2006.
40. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294:2052-2056.
41. US Food and Drug Administration Premarket Approval (PMA) Database: PMA 940025 S003. Available at: http://www.accessdata.fda.gov/scripts/cdrh /cfdocs/cfPMA/PMA.cfm?ID=7442.Accessed February 10, 2005.
42. US Food and Drug Administration Premarket Clearance (510[k]) Database: K021231. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs /cfPMN/pmn.cfm?ID=7920. Accessed February 10, 2005.